Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)

Next Previous
Trial Profile

Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorinostat (Primary) ; Hydroxychloroquine; Regorafenib
  • Indications Colorectal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 23 Jun 2022 Primary endpoint (Efficacy based on progression free survival of vorinostat and hydroxychloroquine compared to Regorafenib) has been met, according to Results published in the British Journal of Cancer.
  • 23 Jun 2022 Results published in the British Journal of Cancer
  • 08 Apr 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top